RSS

Crohn's disease

The first allogenic stem cell therapy — Alofisel (darvadstrocel) from TiGenix and Takeda Pharmaceutical Company — has received marketing authorisation approval from the EC for the treatment of complex perianal fistulas in Crohn’s disease Read more

News

According to data and analytics company, GlobalData, new real-world evidence will support the use of a biosimilar treatment for Crohn’s disease (CD), leading to a boost in the biosimilar market value. Read more

Analysis

Biopharmaceutical company, TiGenix, has submitted responses to the marketing authorisation application for Cx601, a treatment of complex perianal fistulas in Crohn’s disease patients as a first indication. Read more

News